Welcome to the world of Micreos...
Bacteria are all around us. Most of them are good and protect us, but some can cause irritation or infection. Antibiotics do not distinguish between good and bad bacteria and their use can lead to side effects and resistance. As they have been broadly used - often inappropriately - the emergence of antibiotic-resistant 'superbugs' is now a global concern.
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. The company is viewed as global leader spearheading this exciting new field. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria - including antibiotic resistant strains - while leaving the beneficial bacteria intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us - also enabling daily use as long as needed while preserving the important biodiversity on our skin and in our gut.
Micreos' Staphefekt SA.100 is an enzyme (endolysin), which kills only Staphylococcus aureus, including MRSA. It is also suitable for routine maintenance therapy, for inflammatory skin conditions such as eczema, rosacea, psoriasis and inflammatory acne. For further related background information on these topics fact sheets are available.
Micreos also has FDA-approved food safety products: Salmonelex™ against Salmonella and Listex™ against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised.
The company is committed to helping mankind with products that are effective, sustainable and affordable. The company's products:
- work fast
- are easy to apply
- have no known adverse effects
Micreos' technology is applied in many areas, including human health, animal health, food safety and agriculture. Micreos Human Health is based in Bilthoven at the RIVM premises (Dutch NIH). Micreos Food Safety is based in Wageningen 'Food Valley'. Micreos headquarters are based in The Hague, world capital of Peace and Justice.
Micreos has a modern Endolysin and Phage Technology Centre, responsible for GMP-quality Production, Research & Development, and Quality Control. We work according to the highest ethical and professional standards, as witnessed by numerous awards and grants received over the past years, and publications in scientific journals and regular press. Micreos collaborates with top institutes and companies around the world and its advisors and partners have broad expertise in the fields in which we operate. Our long-term research partners include ETH Zurich (Prof. Loessner) and EMCR (Prof. Pasmans, pediatric dermatology).